EGFR and neoplasm: Decisions on first-line treatments are based on the target oncogenes identified in tumor tissues; thus, the tumors of patients with NSCLC should be tested for EGFR mutations to determine whether an EGFR-TKI is the appropriate first-line therapy [3].